cannabis
hopes
drug
firm
prescription
cannabis
drug
made
uk
biotech
firm
gw
pharmaceuticals
set
approved
canada
drug
used
treat
central
nervous
system
alleviate
symptoms
multiple
sclerosis
ms
weeks
ago
shares
gw
pharma
lost
third
value
uk
regulators
said
wanted
evidence
drugs
benefits
canadian
authorities
said
sativex
drug
considered
approval
approximately
people
canada
diagnosed
ms
people
suffering
condition
uk
many
patients
already
smoke
cannabis
relieve
symptoms
gw
pharmas
sativex
mouth
spray
could
legally
available
ms
sufferers
canada
within
next
months
first
time
cannabisbased
drug
approved
anywhere
world
representing
landmark
gw
pharma
patients
ms
final
approval
canada
little
formality
analysts
said
company
expects
full
approval
sativex
early
delighted
receive
qualifying
notice
health
canada
look
forward
receiving
regulatory
approval
sativex
canada
early
part
said
gw
pharma
executive
chairman
dr
geoffrey
guy
uk
government
granted
gw
pharma
licence
grow
cannabis
plant
medical
research
purposes
satifex
consists
cannabis
extract
containing
tetrahydrocannabinol
cannabidiol
cocktail
also
proved
effective
treating
patients
arthritis
thousands
plants
grown
secret
location
somewhere
english
countryside
despite
hopes
regulatory
approval
last
year
series
delays
put
back
sativexs
launch
uk
latest
news
sent
shares
gw
pharma
p
p
